2013
DOI: 10.5214/ans.0972.7531.200207
|View full text |Cite
|
Sign up to set email alerts
|

Soluble Guanylate Cyclase a1–Deficient Mice: A Novel Murine Model for Primary Open Angle Glaucoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 3 publications
0
2
0
Order By: Relevance
“…Because of this property, guanylate cyclase activators have been proposed as therapeutic agents for glaucoma [26,27]. In addition, it has been reported that a KO mouse for the α-1 subunit of soluble guanylate cyclase developed glaucoma [36]. Based on these data, we hypothesize that the loss of GUCA1C function could result in decreased cGMP, increased IOP, and glaucoma.…”
Section: Discussionmentioning
confidence: 78%
“…Because of this property, guanylate cyclase activators have been proposed as therapeutic agents for glaucoma [26,27]. In addition, it has been reported that a KO mouse for the α-1 subunit of soluble guanylate cyclase developed glaucoma [36]. Based on these data, we hypothesize that the loss of GUCA1C function could result in decreased cGMP, increased IOP, and glaucoma.…”
Section: Discussionmentioning
confidence: 78%
“…Because of this property, guanylate cyclase activators have been proposed as therapeutic agents for glaucoma [32,33]. In addition, it has been reported that a KO mouse for the alpha-1 subunit of soluble guanylate cyclase developed glaucoma [34]. Based on these data, we hypothesize that the loss of GUCA1C function could result in decreased cGMP, increased IOP, and glaucoma.…”
Section: Discussionmentioning
confidence: 79%